B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ABL1

MOLECULAR TARGET

ABL proto-oncogene 1, non-receptor tyrosine kinase

UniProt: P00519NCBI Gene: 2521 compounds

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) is targeted by 21 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ABL1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Sorafenib3.9551
2Axitinib3.6638
3Dasatinib3.4731
4Crizotinib3.0420
5Afatinib2.7715
6Avapritinib1.393
7Biotin1.393
819-((1'S,4'R)-4'-hydroxy-1'-methoxy-2'-oxopentyl)geldanamycin [Supplementary Concept]1.393
9Imatinib Mesylate1.393
10triolimus [Supplementary Concept]1.393
11tyrphostin ag 14781.102
12Genistein0.691
13myricetin-3-O-galactopyranoside [Supplementary Concept]0.691
14pterostilbene0.691
15Quercetin0.691
16Adenosine Triphosphate0.691
17alpelisib0.691
18alsterpaullone0.691
19kenpaullone0.691
20Nocodazole Nocodazole is0.691
21Oxytetracycline0.691

About ABL1 as a Drug Target

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 21 compounds with documented ABL1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ABL1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.